Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Experts discuss benefits of combining deworming, school feeding programs at meeting with U.K. Parliament

This post in the Global Network for Neglected Tropical Diseases' "End the Neglect" blog reports on an event held on Wednesday in London during which John Kufuor, former president of Ghana and winner of the 2011 World Food Prize, addressed the U.K. Parliament "about how school feeding programs can help millions of people currently living in poverty."

10 Feb 2012

New cERD method can detect RNAi activity in biological fluids

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its scientists have discovered a novel method for monitoring RNAi activity in blood samples, representing a potential major advance for future development of RNAi therapeutics, other therapeutic modalities, and diagnostics.

10 Feb 2012

Cancer-related fatigue linked to muscle mass and strength

Many patients with advanced cancer suffer from cachexia, a condition also called body-wasting or wasting syndrome, which causes significant weight loss, extreme fatigue and reduces quality of life.

10 Feb 2012

Genzyme announces four-year data from eliglustat tartrate phase 2 trial on Gaucher disease type 1

Genzyme, a Sanofi company, announced today four-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate.

8 Feb 2012

Change in sickle cell anemia prevention strategies decreases racial disparities in stroke-related deaths

The disparity in stroke-related deaths among black and white children dramatically narrowed after prevention strategies changed to include ultrasound screening and chronic blood transfusions for children with sickle cell anemia, according to research presented at the American Stroke Association's International Stroke Conference 2012.

3 Feb 2012

Anemia triples risk of dying within a year after having a stroke

Being anemic could more than triple your risk of dying within a year after having a stroke, according to research presented at the American Stroke Association's International Stroke Conference 2012.

3 Feb 2012

Ligand announces results from melphalan Phase II study on multiple myeloma

Ligand Pharmaceuticals Incorporated announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a poster presentation at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) in San Diego.

2 Feb 2012

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis announced today that following a priority review, the US Food and Drug Administration has approved an update to the Gleevec (imatinib mesylate) tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial.

1 Feb 2012

Clazosentan reduces risk of blood vessel spasm in patients with brain aneurysm

An experimental drug, clazosentan, reduced the risk of blood vessel spasm in patients with a brain aneurysm, according to research presented at the American Stroke Association's International Stroke Conference 2012.

1 Feb 2012

Major effort to tackle neglected tropical diseases

Thirteen drug companies, the governments of the United States, Britain and the United Arab Emirates, the World Bank, the Bill and Melinda Gates Foundation, the Lions Club and other smaller charitable organizations on Monday announced a joint effort to tackle 10 neglected tropical diseases in a coordinated fashion.

31 Jan 2012

Interim results from Allos Therapeutics' FOLOTYN and bexarotene Phase 1 combination study on CTCL

Allos Therapeutics, Inc. today reported interim results from the Company's ongoing Phase 1 combination study of FOLOTYN and bexarotene in patients with relapsed or refractory cutaneous T-cell lymphoma.

31 Jan 2012

Alnylam receives U.S. patent allowance for LNP platform

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application number 12/813,448, covering the company's proprietary second generation lipid nanoparticle (LNP) platform, including the "MC3" lipid.

30 Jan 2012

Research advances understanding of hypoxic response

A new family of proteins which regulate the human body's 'hypoxic response' to low levels of oxygen has been discovered by scientists at Barts Cancer Institute at Queen Mary, University of London and The University of Nottingham.

30 Jan 2012

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

AMAG Pharmaceuticals, Inc. today announced the completion of patient enrollment in the second of the company's two phase III studies that comprise its global registrational program for Feraheme (ferumoxytol) in patients with iron-deficiency anemia (IDA) who are not candidates for oral iron, regardless of the underlying cause.

30 Jan 2012

Viewpoints: Health care is MIA in the State of the Union; Gingrich's earnings for health views

President Obama's largest legislative accomplishment to date was the passage of the health care reform law, which has been going into effect in stages, with regulations currently being written for the most substantial changes due to take effect in 2014. So it is odd the President mentioned health care only briefly, and in passing, in his State of the Union address last night.

27 Jan 2012

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

From Baxter International Inc. 24 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

New federal drug label recommendations for CKD patients

The U.S. Food and Drug Administration (FDA) recently recommended that clinicians be more conservative when they prescribe chronic kidney disease (CKD) patients with drugs that treat red blood cell deficiencies. But the drug label's recommendations fall short, according to two commentaries appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

20 Jan 2012

Platelet receptor could help with diseases that impact RBCs

A receptor found on blood platelets whose importance as a potential pharmaceutical target has long been questioned may in fact be fruitful in drug testing, according to new research from Michigan State University chemists.

20 Jan 2012

Anemia News and Research

Further Reading

Experts discuss benefits of combining deworming, school feeding programs at meeting with U.K. Parliament

New cERD method can detect RNAi activity in biological fluids

Cancer-related fatigue linked to muscle mass and strength

Genzyme announces four-year data from eliglustat tartrate phase 2 trial on Gaucher disease type 1

Change in sickle cell anemia prevention strategies decreases racial disparities in stroke-related deaths

Anemia triples risk of dying within a year after having a stroke

Ligand announces results from melphalan Phase II study on multiple myeloma

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Clazosentan reduces risk of blood vessel spasm in patients with brain aneurysm

Major effort to tackle neglected tropical diseases

Interim results from Allos Therapeutics' FOLOTYN and bexarotene Phase 1 combination study on CTCL

Alnylam receives U.S. patent allowance for LNP platform

Research advances understanding of hypoxic response

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

Viewpoints: Health care is MIA in the State of the Union; Gingrich's earnings for health views

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

New federal drug label recommendations for CKD patients

Platelet receptor could help with diseases that impact RBCs

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News